Laboratory Expansion to Accelerate Sales in USA
Cizzle Biotechnology Holdings PLC
03 August 2026
3 August 2026
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Further Laboratory Expansion to Accelerate Sales in USA
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to note that the Company's North American licensing partner, Cizzle Bio Inc ("BIO"), has today announced it has executed a strategic laboratory agreement with BioBridge Global ("BBG"), a San Antonio-based healthcare services organisation with expertise in laboratory medicine, biomanufacturing, blood banking and translational science. This is the second commercial agreement with a clinical laboratory group as BIO rolls out its implementation programme to deliver the Company's proprietary CIZ1B Biomarker Blood Test for Lung Cancer (the "Test")
Under the terms of the agreement, BBG Advanced Therapies, a subsidiary of nonprofit BBG, will serve as a Clinical Laboratory Improvement Amendments ("CLIA") certified laboratory partner offering the Test for lung cancer to licensed healthcare providers across South Texas, USA.
Because the Test is a laboratory-developed test ("LDT"), each CLIA-certified laboratory performing the assay must complete independent validation to verify analytical performance and meet rigorous quality standards. BBG Advanced Therapies has initiated this validation process and, upon completion, will become an additional CLIA-certified laboratory offering the Test to licensed healthcare providers in South Texas.
The agreement is designed to advance BIO's broader commercialisation strategy to expand national access to a high-impact, minimally invasive biomarker blood test in regions facing a significant lung cancer burden and health disparities. This collaboration is part of BIO's phased national strategy to build a network of high-quality laboratory partners offering the Test to licensed healthcare providers across the United States.
On 16 June 2026, the Company announced the Test had successfully completed laboratory validation and is approved for use under CLIA at OmniHealth Diagnostics ("OmniHealth"). With initial sales under way at OmniHealth, BIO is rapidly adding to its portfolio of additional CLIA-certified laboratory partners across the United States.
The full BIO press release can be read at: http://www.rns-pdf.londonstockexchange.com/rns/0238P_1-2026-8-3.pdf
Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:
"After decades of research and development, the Company's CIZ1B biomarker test for early-stage lung cancer is now benefiting patients with initial sales having commenced at OmniHealth. Our licensing partner, BIO, is addressing the challenge of rolling out with selected clinical laboratories to enable the Test to be delivered at scale not just in Texas, but across all areas of the U.S., Canada and the Caribbean."
Commenting, Bill Behnke, founder and CEO of BIO, said:
"Early detection can dramatically improve outcomes, yet too many patients are diagnosed after lung cancer has progressed. Our collaboration with BBG represents an important step toward expanding access to the CIZ1B Biomarker Blood Test across South Texas and advancing our commitment to help healthcare providers detect lung cancer earlier, when patients may have more treatment options."
Marty Landon, Chief Executive Officer of BioBridge Global, said:
"Collaborating with Cizzle Bio brings together their innovative biomarker technology with BBG's expertise in laboratory operations, quality systems and regulatory compliance. By combining our strengths, we're helping expand access to advanced early detection cancer screening while ensuring health care providers have confidence in the quality and reliability of the testing they offer their patients."
Adrienne Mendoza, Chief Operating Officer of BioBridge Global, added:
"Innovation only changes lives when patients can access it. This collaboration reflects BBG's commitment to working alongside pioneering organizations like Cizzle Bio to help translate scientific advances into real-world healthcare solutions. Together, we're expanding access to an innovative test that has the potential to improve patient care and strengthen the health of the communities we serve."
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
Allenby Capital Limited (Financial Adviser) |
+44(0) 20 3328 5656 |
|
John Depasquale (Corporate Finance) |
|
|
Zeus (Corporate Broker) James Hornigold, Alex Slater (Investment Banking) Nick Searle (ECM) |
+44(0) 20 3829 5000 |
|
IFC Advisory Limited |
+44(0) 20 3934 6632 |
|
Tim Metcalfe |
|
|
Florence Staton |
About Cizzle Biotechnology
The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer. In June 2026, the test was successfully accredited for clinical use in the United States under the Clinical Laboratory Improvement Amendments (CLIA) at OmniHealth Diagnostics, providing a regulated laboratory route to market and enabling licensed US healthcare providers to order the test.
Cizzle has entered into commercial royalty-bearing licensing arrangements covering North America and the Caribbean and continues to work with commercial partners and centres of excellence in cancer care to support the clinical adoption and wider commercialisation of its proprietary diagnostic technologies.
Cizzle was admitted to the Official List and Main Market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
About Cizzle Bio
Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing novel biomarker-based blood tests. The company's goal is to empower patients, equip clinicians and improve outcomes through innovative, compassionate and life-saving solutions. Cizzle Bio holds exclusive licensing rights for its groundbreaking CIZ1B Biomarker Blood Test for Lung Cancer in the United States, Canada and the Caribbean.
For more information, please see: cizzlebio.com
About BioBridge Global
BioBridge Global is a San Antonio-based 501(c)(3) nonprofit healthcare services enterprise that offers diverse services through its nonprofit subsidiaries - South Texas Blood & Tissue, QualTex Laboratories, BBG Advanced Therapies and The Blood & Tissue Center Foundation. BioBridge Global provides products and services in blood resource management, cellular therapy, donated umbilical cord blood and human tissue, as well as testing of blood, plasma and tissue products for clients in the United States and worldwide. The enterprise enables advances in the field of regenerative medicine and advanced therapies by providing access to starting materials, testing services as well as biomanufacturing and clinical trials support. BioBridge Global is committed to saving and enhancing lives through the healing power of human cells and tissue.
Learn more at BioBridgeGlobal.org
About BBG Advanced Therapies
BBG Advanced Therapies, a subsidiary of BioBridge Global, provides innovative and custom solutions to accelerate the development of cell and gene therapies. BBG Advanced Therapies features a fully integrated and custom portfolio of innovative solutions, including collection and processing of starting materials, testing, clinical trials support, and biomanufacturing services.
Learn more at BBGAdvancedTherapies.org
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.